Objectives: Assess the cost-effectiveness of the combination between Polatuzumab (POLA) in combination with rituximab (R) and bevacizumab (B) against Rituximab and bevacizumab in patients with relapsed/refractory diffuse large B-cell lymphomab (DLBCL). Methods: A partitioned survival model was adapted to represent the natural history of disease, and to estimate the economic and health benefits. The survival analysis was performed using IPD from GO29365 trial with parametric and cure mixture methods. The expected costs were measured in Chilean pesos (USD$1= CLP$702.63) and health benefits in quality adjusted life years (QALYs). The QALYs were estimated from utilities obtained from literature. A time horizon of 25 years and 3% discount rate were considered for cost and benefits. A probabilistic sensibility analysis was performed in order to characterize the second order uncertainty. Results: The total expected costs of treating the R/R DLBCL with the combination of POLA with R+B were higher than R+B (incremental cost POLA R+B vs R+B: $27,327.2). The estimated QALYs for POLA with R+B were the highest (incremental QALYs POLA R+B vs R+B: 1.20 QALYs). The base case scenario shows an ICER for POLA R+B vs R+B of $22,746.7 and $12,647.7/QALY for the scenario analysis. The DSA shows the utility in PD as the variable with the widest variability. At suggested threshold of $14,943.8 (1xGDP per capita in Chile), the CEAC shows that POLA with R+B has a 52% to be a cost-effectiveness alternative in comparison with R+B. Conclusions: The combination treatment of Polatuzumab with Rituximab and Bendamustina has showed to be the alternative that produced more QALYs , but it was more expensive, hence the new interventions was not a cost-effectiveness alternative at 1 GDP per capita to treat the R/R DLBCL, but It was cost-effective using a threshold of 2 GDP per capita.